Background: Fatty-acid-binding proteins (FABPs) are intracellular carriers for endocannabinoids, N-acylethanolamines, and related lipids. Previous work indicates that systemically administered FABP5 inhibitors produce analgesia in models of inflammatory pain. It is currently not known whether FABP inhibitors exert their effects through peripheral or central mechanisms. Here, we examined FABP5 distribution in dorsal root ganglia and spinal cord and examined the analgesic effects of peripherally and centrally administered FABP5 inhibitors. Results: Immunofluorescence revealed robust expression of FABP5 in lumbar dorsal root ganglia. FABP5 was distributed in peptidergic calcitonin gene-related peptide-expressing dorsal root ganglia and non-peptidergic isolectin B4-expressing dorsal root ganglia. In addition, the majority of dorsal root ganglia expressing FABP5 also expressed transient receptor potential vanilloid 1 (TRPV1) and peripherin, a marker of nociceptive fibers. Intraplantar administration of FABP5 inhibitors reduced thermal and mechanical hyperalgesia in the complete Freund's adjuvant model of chronic inflammatory pain. In contrast to its robust expression in dorsal root ganglia, FABP5 was sparsely distributed in the lumbar spinal cord and intrathecal administration of FABP inhibitor did not confer analgesic effects. Administration of FABP inhibitor via the intracerebroventricular (i.c.v.) route reduced thermal hyperalgesia. Antagonists of peroxisome proliferator-activated receptor alpha blocked the analgesic effects of peripherally and i.c.v. administered FABP inhibitor while antagonism of cannabinoid receptor 1 blocked the effects of peripheral FABP inhibition and a TRPV1 antagonist blocked the effects of i.c.v. administered inhibitor. Although FABP5 and TRPV1 were co-expressed in the periaqueductal gray region of the brain, which is known to modulate pain, knockdown of FABP5 in the periaqueductal gray using adeno-associated viruses and pharmacological FABP5 inhibition did not produce analgesic effects. Conclusions: This study demonstrates that FABP5 is highly expressed in nociceptive dorsal root ganglia neurons and FABP inhibitors exert peripheral and supraspinal analgesic effects. This indicates that peripherally restricted FABP inhibitors may serve as a new class of analgesic and anti-inflammatory agents.
Introduction
Chronic pain affects between 30% and 60% of older adults. [1] [2] [3] Inflammatory pain is typically treated with non-steroidal anti-inflammatory drugs such as ibuprofen. 4 However, prolonged use of non-steroidal anti-inflammatory drugs is associated with significant side-effects including gastrointestinal ulceration and bleeding. 4, 5 Opioids are another class of highly efficacious analgesics for the treatment of acute pain but lose efficacy with chronic usage. 6 Furthermore, opioids are highly addictive and many patients administered chronic opioids develop addiction. [7] [8] [9] Consequently, there is a pressing need to develop novel efficacious, non-addictive analgesics for the treatment of chronic pain.
Fatty-acid-binding proteins (FABPs) are intracellular lipid chaperones that are expressed in cells of the central and peripheral nervous system. [10] [11] [12] In addition to fatty acids, FABPs interact with other endogenous lipids including the endocannabinoids, anandamide (AEA) and 2-arachidonoylglycerol (2-AG), and related N-acylethanolamines (NAEs). [13] [14] [15] [16] FABPs regulate the intracellular delivery of AEA to its catabolic enzyme fatty acid amide hydrolase (FAAH) and FABP inhibition reduces AEA inactivation in vitro and elevates AEA levels in vivo. [13] [14] [15] [16] [17] Similar to FABP inhibition, FAAH inhibitors elevate tissue AEA levels, which subsequently activates central and peripheral cannabinoid receptor 1 (CB1) to produce analgesia. [18] [19] [20] [21] However, FAAH inhibition in liver produces hyperglycemia and insulin resistance, 22 effects not seen with FABP inhibitors. FABP inhibitors do not produce conditioned place preference in mice, 23 suggesting that they are devoid of addictive properties. Consequently, FABP inhibitors may serve as efficacious analgesics and may exhibit a low sideeffect profile.
In addition to AEA, FABPs regulate the metabolism of the NAEs palmitoylethanolamide (PEA) and oleoylethanolamide (OEA), which activate peroxisome proliferator-activated receptor alpha (PPARa) centrally and peripherally and produce analgesic and anti-inflammatory effects. [24] [25] [26] We have previously shown that FABP5 and FABP7 bind to endocannabinoids/NAEs with high affinities and that mice deficient in these proteins exhibit reduced nociception. 14, 26, 27 Furthermore, considering that FABP7 exhibits low expression in adult tissues and the analgesic effects of FABP inhibitors track well with their affinities for FABP5 15, 28 and are lost in FABP5 KO mice (MK, unpublished observations), suggests that FABP5 inhibition likely accounts for the analgesic effects of FABP inhibitors.
We recently reported that the analgesic effects produced by pharmacological or genetic FABP inhibition are mediated by CB1, PPARa, and transient receptor potential vanilloid 1 (TRPV1) receptors. 15, 26 While CB1 and PPARa receptors produce their analgesic effects centrally and peripherally, TRPV1 activation in primary sensory neurons induces pain while its activation in supraspinal regions leads to analgesia. [29] [30] [31] The goal of this study was to profile FABP5 expression in anatomical sites that regulate nociception and to determine whether FABP inhibitors exert their analgesic effects through a central and/or peripheral site of action. In particular, we evaluated FABP inhibition using the parent compound SBFI26, which was identified in our laboratories using a dual computational/experimental screening approach and contains a unique truxillic acid scaffold. 32 Importantly, truxillic acid-based compounds like SBFI26 are similar to the chemical incarvillateine, a molecule identified as the active component of the traditional Chinese medicine Incarvillea sinensis used to treat pain and inflammation. 33 
Materials and methods
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Synthesis of inhibitors
2,4-Diphenylcyclobutane-1,3-dicarboxylic acid (-truxillic acid).
E-Cinnamic acid (2.50 g, mmol) placed in a Pyrex dish and irradiated by a 365-nm mercury lamp (280 mW/cm 2 ) for five days with periodic shaking. The reaction was monitored by 1 H NMR. After 87% conversion had been achieved on day 5, the reaction mixture (white solid) was washed with diethyl ether to remove unreacted E-cinnamic acid, and desired a-truxillic acid was obtained as white powder (2.01 g, 80% yield; 92% conversion yield): 1 32 2,4-Diphenylcyclobutane-1,3-dicarboxylic acid mono-1-naphthyl ester (SBFI26).
a-Truxillic acid (297 mg, 1.0 mmol) was suspended in thionyl chloride (3 mL), and one drop of DMF was added to the suspension. The reaction mixture was heated to reflux for 3 h. The excess thionyl chloride and DMF was removed in vacuo to give truxillic acid dichloride, which was used directly in the subsequent reaction. To a solution of truxillic acid dichloride in THF (10 mL) was added dropwise a solution of 1-naphthol (120 mg, 0.84 mmol) in THF (5 mL) and pyridine (0.5 mL), and the reaction mixture was heated to reflux for 3 h. The reaction was quenched by addition of water (2 mL). The resulted solution was diluted with ethyl acetate (15 mL), and the aqueous layer was separated. The organic layer was dried over MgSO 4 and concentrated in vacuo. The crude product was purified by flashed column chromatography on silica gel using ethyl acetate/hexanes (10%-25% EtOAc gradient) as eluent to afford SBFI26 as white solid (202 1-Methyl 3 -(1-naphthyl) 2,4-diphenylcyclobutane-1,3-dicarboxylate (SBFI26ME).
To a solution of SBFI26 (60 mg, 0.14 mmol) in acetone (5 mL) was added K 2 CO 3 (39 mg, 0.28 mmol) and Me 2 SO 4 (11 mg, 0.09 mmol), and the reaction mixture was heated to reflux for overnight. The reaction mixture was cooled to room temperature and filtered through Celite. The filtrate was concentrated and the residue was purified by column chromatography on silica gel (EtOAc/hexanes, 0%-10% EtOAc gradient) to afford SBFI26ME as a white solid (62 mg, 99%): m. 
Behavioral tests
Mice were habituated to the experimental room for at least two days before baseline measurements and at least 2 h before each experiment. To induce chronic inflammation, mice received unilateral intraplantar injections of 20 mL complete Freund's adjuvant (CFA) (50% in saline) (#F5881, Sigma). Three to seven days later, thermal and mechanical hyperalgesia was measured, respectively, using the Hargreaves plantar apparatus (Ugo Basile) or graded von Frey filaments as previously reported. 15 The experimenter was blinded to the treatment condition of each animal.
Drug administration
For intraplantar drug administration, three to seven days after CFA injections, mice received an injection of 5 mL SBFI26, SBFI26ME, or DMSO using a 30-G needle. Intrathecal injections were performed as described previously with modifications. 34 Briefly, mice were anesthetized with 2% isoflurane, the back was shaved, and 2 mL of SBFI26 (50 mg) or DMSO was slowly injected between the L5 and L6 vertebrae using a 10 -mL Hamilton syringe equipped with a 30-G needle. For experiments involving receptor antagonists, the compounds were injected via the intraperitoneal route 30 min before SBFI26 in a volume of 10 mL/g body weight. Rimonabant (3 mg/kg) was dissolved in ethanol:Cremophor-EL:saline (1:1:18), GW6471 (4 mg/kg), and AMG9810 (30 mg/kg) were dissolved in DMSO:Cremophor-EL:saline (1:1:8).
Stereotaxic surgery and inhibitor administration
Adult mice were anesthetized with an i.p. injection of a surgical mixture of ketamine (100 mg/kg)/xylazine (10 mg/kg). The head was shaved and the scalp cleaned with betadine. The animal was subsequently placed in the stereotaxic instrument (BenchMark Digital, Leica Biosystems, Buffalo Grove, IL) and a 1-cm skin incision was made to reveal the skull. After removing the soft tissue from the surface, the skull was cleaned with 3% hydrogen peroxide and was leveled between the bregma and lambda. The placement of the guide cannula was determined in relation to the bregma, a mark was made on the skull surface, and a small hole was drilled through the skull. The stereotaxic coordinates are established from the atlas of Franklin and Paxinos, 3rd edition, 2008. For the i.c.v. injections, the coordinates were AP: À0.34 mm, ML: 1.0 mm, DV: 2.3 mm. For the dorsolateral PAG, the coordinates were AP: À4.6 mm, ML: 0.5 mm, DV: 2.0 mm. For the ventrolateral PAG, the coordinates were AP: À4.6 mm, ML: 0.5 mm, DV: 2.75 mm. For the RVM injections, the coordinates were AP: À5.8 mm, ML: 0.0 mm, DV: 5.5 mm. A low-profile mouse cannula guide (C315GS-4/SPC, Plastics One, Roanoke, VA) with an infusion dummy cannula (C315DCS-4/SPC, Plastics One, Roanoke, VA) was inserted into skull hole and held in place with Loctite gel. The base of the cannula guide was then cemented onto the skull using dental cement (Ortho-Jet Powder, Lang Dental Manufacturing Co. Inc., Wheeling, IL), and the dummy infusion cannula was replaced with a cap. The animal was allowed to recover from the surgery for a week before behavioral testing.
On the day of the drug injection, the mice were sedated with isoflurane, the dummy cap removed and an internal injection cannula (C315IS-4/SPC, Plastics One, Inc., Roanoke, VA) of the proper length for that brain region inserted through the guide cannula. The injection cannula was connected to a 10 -mL syringe (Hamilton Co., Reno, NV) via PE-50 tubing and 0.2 mL of the either the vehicle or the drug solution was injected over a 2-min period using a GenieTouch syringe pump (Lucca Technologies, Harwinton, CT). The injection cannula was allowed to remain for an additional 60 s before withdrawal and the guide cannula cap replaced. Mice were placed back into their home cages to recover before behavioral testing and testing occurred 2 h after drug administration.
AAV-mediated FABP5 knockdown
The AAVs were generated at the Duke University Viral Vector Core. The AAVs (serotype 5) utilized a chicken beta actin promoter, enhanced green fluorescent protein to gauge transduction efficiency, and expressed FABP5 shRNA or scrambled control. The FABP5 shRNA sequence is as follows: TAACCAAAGGAATGATCCT. Mice were anesthetized with 2% isoflurane and 0.2 mL of AAV (titer of 9.3 Â 10 11 /ml) was infused into the dorsolateral PAG through the cannula at a rate of 0.1 mL per minute using a GenieTouch syringe pump (Lucca Technologies). After 21 days, the mice were employed for behavioral experiments or histology.
Enzyme assays
FAAH activity assays were performed as previously described. 13, 15 Briefly, brain and paw tissues were homogenized in 50 mM Tris-HCl buffer (pH 9) and incubated with 100 mM [ 14 C]AEA at 37 C to permit $10% substrate hydrolysis. The reactions were quenched by the addition of two volumes of 1:1 chloroform:methanol, separated by centrifugation, and the top phase collected and radioactivity quantified using a scintillation counter.
Immunofluorescence
Mice were anesthetized (100 mg/kg ketamine plus 10 mg/ kg xylazine, i.p.) and transcardially perfused with saline followed by 4% paraformaldehyde in 0.1 M phosphate buffered saline (PBS), pH 7.4. Brains, spinal cord, and dorsal root ganglia (DRGs) were dissected and immersed in the same fixative overnight at 4 C; this was followed by immersion in 30% sucrose in 0.1 M PB for cryoprotection. The tissues were embedded in a gelatin-albumin mixture (3% gelatin, 30% egg albumin in dH 2 O) and frozen using a liquid nitrogen-chilled isopentane bath. The blocks were then fixed to a peg and cut using a cryostat at À16
C. The sections of 20 mm in thickness, were thaw-mounted on gelatin/chromium-coated slides, air dried, and stored in a frost-free freezer at À20 C until further processing. Sections were thawed at room temperature for 20 min, the tissues were fixed onto the slides with 4% PFA for 5 min, rinsed in PBS three times for 10 min, and then incubated with 0.2% Triton X-100 (Sigma-Aldrich Cat# 9002-93-1) in PBS 10 min for permeabilization. A 30-min block was used, consisting of 10% normal donkey serum (NDS, Jackson ImmunoResearch Labs Cat# 017-000-121 RRID:AB_2337258), 2% glycine, and 0.1% Triton X-100 in PBS. Tissues were incubated overnight at 4 C with primary antibodies diluted in PBS containing 0.3% Triton X-100 and 5% NDS. Primary antisera used were rabbit anti-FABP5 (BioVendor, #RD181060100, RRID:AB_344491) at 1:800 dilution in brain and 1:600 in DRGs, mouse anti-TRPV1 (UC Davis/ NIH NeuroMab, #75-254, RRID:AB_11000725) at 1:400 dilution in brain tissue, goat anti-TRPV1 (Neuromics, #GT15129-100, RRID:AB_2209002) at 1:100 dilution in DRGs, mouse anti-peripherin (Millipore, #MAB5380, RRID:AB_2171352) at 1:75 dilution, goat anti-FAAH (LifeSpan Cat# LS-B4126-50 RRID:AB_10720351) at 1:50 in DRGs, and goat anti-CGRP (AbD Serotec Cat# 1720-9007 RRID:AB_2290729) at 1:400 in DRGs. The sections were washed three times for 10 min each in PBS. The slides were incubated for 1 h at room temperature with secondary antibodies diluted in PBS with 0.3% Triton X-100 and 5% NDS. 
Western blotting
Immunoblots were performed essentially as described. 26 The blots were probed with rabbit anti-FABP5 (1:1000, BioVendor #RD181060100, RRID:AB_344491) and mouse anti-beta actin (1:10,000, Abcam #ab6276, RRID:AB_2223210) antibodies followed by HRPlabeled secondary antibodies. The blots were developed using the Clarity Western HRP substrate (Bio-Rad) and scanned using a C-DiGiT scanner (Li-COR). Protein band intensities were quantified and normalized to beta actin intensities.
Lipid quantification
Tissue endocannabinoid levels were quantified as previously described with minor modifications. 15 Mice were euthanized by rapid decapitation and brain and paw tissues were flash frozen in liquid nitrogen. The samples were thawed on ice, weighed, spiked with deuterated standards, homogenized, and quantifications performed as described. 15 SBFI26 quantification was performed as previously described using an external calibration curve. 15 For SBFI26ME quantification, paw tissues were flash frozen in liquid nitrogen and homogenized in 4 ml of 2:1:1 chloroform:methanol:Tris (50 mM, pH 8), the phases separated by centrifugation, and the chloroform phase isolated and dried down under gentle argon stream. The samples were subsequently resuspended in 50% acetonitrile in water and injected into a Thermo TSQ Quantum Access Triple Quadrupole Mass Spectrometer (Thermo-Fisher) at a flow rate of 5 mL/min. Liquid chromatography separation was achieved on a Luna C18 (150 Â 2 mm, 5 mm) column. Mobile phase A was composed of 5 mM ammonium acetate while mobile phase B was composed of 100% acetonitrile. A linear gradient was used and started at 50% phase B for 2 min, ramped to 95% phase B in 10 min, and was followed by a 5-min hold at 95% phase B. The system was equilibrated at 50% phase B for 10 min. Quantification was performed in positive ion mode. The following parameters were employed: high voltage was set at 4.5 kV, the sheath pressure was 55 psi, and the capillary was set to 350 C. Multiple reaction monitoring was used with the transition m/z 454 to 131 at 25 eV as the quantitation channel with m/z 454 to 275 at 15 eV serving as the confirmation channel.
Dissociated DRG neurons
Mice were deeply anesthetized with isoflurane and decapitated. The lumbar segments of the spinal cord were removed and placed in a cold Ca C (in 5% CO 2 ) and used over the next 4-6 h. Small DRG neurons (diameters < 27 mm) were selected by measuring the diameter from images captured to a computer by a digital camera (ORCA-Flash4.0, Hamamatsu Corporation, Bridgewater, NJ, USA).
Calcium imaging in isolated DRG neurons
Dissociated DRG neurons were loaded with 5 mM fura-2AM and maintained in a modified Tyrode's solution containing (in mM): 151 NaCl, 2 CaCl 2 , 1 MgCl 2 , 2.5 KCl, 10 HEPES, 13 glucose, pH 7.4 with NaOH. DRG neurons loaded with fura-2AM were identified by calcium fluorescence by exciting the fluorophore at 340 nm wavelength illumination (Lambda XL, Sutter Instruments, Novato, CA) for 300 ms. The fluorophore was then excited alternately (300 ms) with 340 and 380 nm wavelength illumination. Images were acquired using the ORCA-Flash4.0 digital camera at a rate of 0.33 Hz. The fluorescence ratio for individual neurons was determined as the intensity of emission during 340 nm excitation (I340) divided by 380 nm emission (I380) and used as an indicator of change in cytoplasmic calcium. 35 The I340/I380 ratio was calculated on a pixelby-pixel basis using the MetaFluor software (Molecular Devices, Sunnyvale, CA, USA). Activation of TRPV1 channels was triggered by 1 mM capsaicin. Capsaicin or the test drug were applied using an array of quartz fiber flow pipes (500 mm internal diameter) positioned about 1 mm away from DRG neurons.
Statistical analysis
Data are presented as means AE SEM. Statistical significance was determined using two-tailed t tests between groups, one-way analysis of variance (ANOVA) followed by Dunnett or Tukey post hoc analysis, or twoway ANOVA followed by Bonferroni post hoc analysis. In all cases, differences of p < 0.05 were considered significant. (g) Levels of SBFI26ME and SBFI26 in paws 2 h after intraplantar administration of 50 mg SBFI26ME (n ¼ 3). 
Results
Peripheral analgesic effects of FABP inhibitors
Primary sensory neurons innervate the extremities and transmit noxious stimuli to projection neurons in the dorsal horn of the spinal cord. 36, 37 We examined the expression of FABP5 in DRG of primary sensory neurons. In lumbar DRGs, FABP5 showed robust expression in small and large diameter neurons, consistent with previous results. 10 Specifically, FABP5 was expressed in 50.3% of ''peptidergic'' calcitonin gene-related peptide (CGRP)-positive and in 48.2% of ''non-peptidergic'' isolectin B4 (IB4)-positive neurons ( Figure 1(a) ; Table 1 ). CGRP-positive and IB4-positive primary sensory neurons transmit noxious thermal and mechanical stimuli. [38] [39] [40] [41] In our previous work, we have shown that FABP5 inhibition reduces thermal hyperalgesia. 15, 26, 32 In nociceptors, thermal pain is transduced by the TRPV1 channel. 29, 30 Consequently, we examined whether FABP5 is co-expressed with TRPV1 in DRG neurons. Indeed, our data demonstrate robust coexpression of FABP5 and TRPV1, with FABP5 expression being present in $76% of TRPV1 þ DRGs ( Figure 1(b) ; Table 1 ). Lastly, FABP5 was also expressed in DRGs expressing peripherin, a marker of nociceptors (Figure 1(c) ).
The robust expression of FABP5 in sensory neurons suggests that the analgesic effects of FABP inhibitors may be mediated via peripheral FABP inhibition. To examine this directly, we employed the CFA model of chronic inflammatory pain, which results in profound thermal and mechanical hyperalgesia (Figure 2) . To inhibit FABP5, we employed the FABP inhibitor SBFI26, which was previously described ( Figure  (2a) ). 15, 32 Intraplantar injection of SBFI26 dose-dependently reduced mechanical hyperalgesia (Figure 2(b) ). Injection of SBFI26 into the contralateral paw did not affect mechanical sensitivity of the CFA-injected ipsilateral paw (Figure 2(c) ), arguing against a systemic effect of the compound. In addition to mechanical thresholds, intraplantar administration of SBFI26 likewise reduced thermal hyperalgesia (Figure 2(c)) . A time course of SBFI26 analgesic effects indicates that the compound maintains efficacy for 4 h after administration (Figure 2(d) and (e)). We also examined paw tissue levels of SBFI26 after intraplantar injection and observed a rapid decline in SBFI26 1 h after administration and continued reductions thereafter (Figure 2(f) ). SBFI26ME is a novel congener of SBFI26 wherein the carboxylate is conjugated with a methyl ester ( Figure  (2a) ). After systemic administration, SBFI26ME metabolism converts the compound into SBFI26 (MK, unpublished observations). In contrast, intraplantar injection of SBFI26ME does not lead to appreciable conversion into SBFI26 (Figure 2(g) ), suggesting that paw tissue may lack the necessary esterases to hydrolyze the methyl ester moiety. Consistent with its low affinity for FABP5 (K i > 10 mM), intraplantar administration of SBFI26ME did not affect mechanical thresholds in CFA-treated mice (Figure 2(b) ). These data provide strong evidence that inhibition of peripherally expressed FABPs produces analgesic effects.
Central analgesic effects of FABP inhibitors
Sensory neurons that transmit noxious stimuli terminate in lamina I and lamina II of the dorsal horn of the spinal cord. 36 Consequently, we examined FABP5 distribution in the lumbar spinal cord and observed uniform distribution of the protein, which was not concentrated in lamina I or lamina II (Figure 3(a) ). Additionally, FABP5 was not expressed in the terminals of sensory neurons as indicated by a lack of co-localization with CGRP in the dorsal horn of the spinal cord (Figure 3(b) ). Accordingly, intrathecal administration of SBFI26 did not affect thermal or mechanical thresholds in CFA-injected mice (Figure 4(a) and (b) ). In addition to the spinal cord, FABP5 is expressed throughout the brain and FABP5 inhibition elevates brain endocannabinoid and NAE levels. 15, 26 Furthermore, supraspinal sites such as the periaqueductal gray (PAG) influence the descending control of pain 42 and activation of CB1 within the PAG produces analgesia. 43 Consequently, we examined whether supraspinal FABP inhibition reduces nociception. Intracerebroventricular (i.c.v.) administration of SBFI26 reduced thermal hyperalgesia in CFA-injected mice (Figure 4(c) ) but did not affect mechanical thresholds (Figure (4d) ).
Anatomically specific engagement of CB1, PPAR, and TRPV1 receptors mediates the analgesic effects of FABP inhibitors
We have previously demonstrated that CB1, PPARa, and TRPV1 receptors are responsible for the analgesic effects of systemically administered FABP inhibitors and in FABP5/7 KO mice. 15, 26 We next sought to determine the receptor systems that mediate the analgesic effects of FABP inhibitors at each anatomical site. Treatment of mice with the CB1 antagonist rimonabant or the PPARa antagonist GW6471 blocked the analgesic effects of intraplantar SBFI26 (Figure 5(a) and (b) ). GW6471 similarly blocked the analgesic effects of i.c.v. administered SBFI26 while rimonabant was without effect ( Figure  5(c) ). These data indicate that peripheral and central FABP inhibition results in the engagement of distinct receptor systems.
The inability of rimonabant to block the analgesic effects of i.c.v. administered SBFI26 may have stemmed from the inability of SBFI26 to elevate brain AEA levels. Quantification of brain endocannabinoid/NAE levels revealed that SBFI26 elevated AEA and in addition also raised PEA and OEA levels (Figure 6(a) ). We also profiled paw tissue levels of endocannabinoids/NAEs and observed that SBFI26 did not affect PEA, OEA, AEA, or 2-AG levels ( Figure 6(b) ). This is perhaps not surprising given that previous reports found that inhibition of FAAH, the principal enzyme that hydrolyzes AEA, likewise does not elevate plantar levels of AEA despite producing CB1-mediated analgesic effects. 44, 45 Importantly, intraplantar and i.c.v. administration of SBFI26 did not inhibit FAAH activity (Figure 6 (c) and (d)), confirming that the effects of SBFI26 upon endocannabinoid levels are unlikely to be a result of off-target inhibition of FAAH.
Previous studies have demonstrated that activation of supraspinal TRPV1 receptors reduces nociception, 31, 46 and we have recently reported that the analgesic effects observed in FABP5/7 KO mice were mediated by TRPV1. 47 AEA is an agonist at TRPV1 and its levels are elevated following i.c.v. administration of SBFI26. Therefore, we examined whether blocking TRPV1 receptors reduces the analgesic effects of i.c.v. SBFI26. Indeed, the TRPV1 antagonist AMG9810 significantly attenuated analgesia produced by i.c.v. SBFI26 ( Figure  5(c) ). In contrast, AMG9810 did not affect analgesia produced by intraplantar SBFI26 (Figure 5(a) ), and it did not significantly alter thermal hyperalgesia when administered alone into CFA-treated animals ( Figure  5(d) ). To rule out the possibility that SBFI26 directly activates TRPV1, freshly dissociated DRG neurons were incubated with the TRPV1 agonist capsaicin (1 mM) or SBFI26 (10 mM) and TRPV1 activation was examined by calcium imaging. Our results indicate that SBFI26 does not activate TRPV1 (Figure 7 ). In contrast and as expected, capsaicin robustly activated TRPV1 receptors. Collectively, these data indicate that FABP inhibition potentiates supraspinal TRPV1 activation by elevating the levels of endogenous TRPV1 ligands such as AEA.
The PAG does not mediate the analgesic effects of supraspinal FABP inhibition
The PAG is an important brain region that regulates the descending control of pain. 42 Furthermore, activation of TRPV1 within the dorsolateral and ventrolateral PAG reduces thermal hyperalgesia. 31, [48] [49] [50] Given that the analgesic effects of centrally administered FABP inhibitor were mediated by TRPV1, we examined whether FABP5 and TRPV1 co-localize within the PAG. Indeed, we observed robust expression of FABP5 in the PAG, which co-localized with TRPV1 (Figure 8(a)  and (b) ).
We subsequently examined whether the PAG mediates the analgesic effects of FABP inhibitors and whether this is mediated via TRPV1 inhibition. To determine whether FABP5 inhibition reduces nociception within the dorsolateral PAG, we knocked down FABP5 expression using adeno-associated viruses (AAVs) bearing shRNA targeting FABP5. Robust transduction within the dorsolateral PAG was observed as indicated by green fluorescent protein (GFP) fluorescence ( Figure  9 (a) and (b)). AAVs bearing FABP5 shRNAs reduced FABP5 expression in the dorsolateral PAG by $55% as indicated by Western blotting (Figure 9 (c) and (d)) and elevated AEA levels ( Figure 9(e) ). Despite the robust FABP5 knockdown and concomitant increase in AEA, thermal hyperalgesia after CFA injection was similar between mice expressing FABP5 shRNA and control mice (Figure 9(f) ).
To eliminate the possibility that the shRNA approach did not produce sufficient knockdown to unmask analgesic effects, we administered 10 mg of SBFI26 into the dorsolateral PAG and examined effects upon thermal hyperalgesia. Similar to the AAV approach, SBFI26 did not affect thermal withdrawal latencies in CFA mice (Figure 9(g) ). Lastly, SBFI26 was injected into the ventrolateral PAG and similarly failed to affect thermal hyperalgesia in CFA mice (Figure 9(h) ). Collectively, these results indicate that the PAG is unlikely to mediate the analgesic effects resulting from supraspinal FABP inhibition.
In addition to the PAG, recent work indicates that endocannabinoid/NAE modulation of rostral ventromedial medulla (RVM) output can regulate nociception. 51 Consequently, we examined whether FABP inhibition within the RVM produces analgesia. SBFI26 (10 mg) or vehicle were injected into the RVM and thermal withdrawal latencies were measured in CFA-treated mice. Similar to the PAG, intra-RVM injection of SBFI26 did not produce antinociceptive effects ( Figure  10 ).
Discussion
Endocannabinoids and NAEs reduce nociception through engagement of central and peripheral CB1 and PPARa receptors 25, 47 as well as central TRPV1. 48 Endocannabinoid inactivation proceeds through cellular uptake followed by intracellular transport by FABPs and subsequent hydrolysis by FAAH. 13, 52 Consequently, FABP inhibition may serve as a novel strategy for the development of analgesic and anti-inflammatory drugs. 15, 32 To aid in the design of future FABP inhibitors, an anatomical dissection of site(s) mediating FABP inhibitor-induced analgesia is required and was the goal of the current work.
The robust expression of FABP5 in lumbar DRGs suggests that FABPs may regulate peripheral endocannabinoid metabolism and that the analgesic effects of FABP inhibitors may be peripherally mediated. Indeed, intraplantar administration of the FABP inhibitor SBFI26, but not its inactive analog SBFI26ME, significantly reduced thermal and mechanical hyperalgesia through a mechanism mediated by CB1 and PPARa receptors. This is consistent with our recent work demonstrating that CB1 and PPARa receptors mediate the analgesic effects of systemically administered SBFI26 and in FABP5/7 KO mice. 15, 26 Similarly, peripheral FAAH inhibition likewise produces CB1 and PPARamediated analgesic effects. 21 This suggests that FABP5 may regulate the availability of endocannabinoids/NAEs for hydrolysis by FAAH, with FABP inhibition reducing endocannabinoid metabolism. Indeed, we observed robust co-expression of FABP5 and FAAH in lumbar DRGs and FABP inhibition elevated the levels of AEA in DRG neurons (Figure 11) .
The finding that peripheral FABP inhibition reduces nociception is important from a drug design perspective as it may enable the development of peripherally restricted FABP inhibitors, which may possess improved safety profiles over brain-penetrant compounds. After systemic administration, only a small fraction of SBFI26 permeates into the brain, 15 possibly suggesting that its major site of action is in peripheral tissues. Indeed, both systemic and intraplantar SBFI26 administration produces analgesic effects mediated by CB1 and PPARa receptors as is seen with peripherally restricted FAAH inhibitors. 21 Our findings uncovered distinct analgesic effects between peripherally and centrally administered FABP inhibitors. FABP5 possesses a diffuse expression pattern in the lumbar spinal cord and its expression was not concentrated in the dorsal horn, the major relay area of the spinal cord that transmits noxious stimuli from primary sensory neurons to higher brain centers. 36 Consequently, intrathecal FABP inhibitor administration did not alter nociception. In contrast to the spinal cord, FABP5 is widely expressed in the brain including areas that regulate pain such as the PAG. 53 Indeed, administration of SBFI26 via the i.c.v. route reduced thermal hyperalgesia, an effect that was mediated by PPARa and TRPV1, but not CB1 receptors. We also recently reported that FABP5/7 KO mice exhibit analgesic effects mediated by PPARa and TRPV1, 26 indicating that the engagement of these receptor systems is not unique to pharmacological FABP inhibition. The inability of centrally administered FABP inhibitors to produce CB1-mediated effects was surprising in light of the elevated AEA levels observed after inhibitor administration ( Figure 6 ). This may suggest that FABPs may not only regulate intracellular endocannabinoid transport and catabolism but may likewise control the delivery of endocannabinoids to CB1 receptors.
We sought to characterize the supraspinal site of action of FABP inhibitors and focused upon the PAG because it is a key brain region that mediates the analgesic effects of exogenous cannabinoids and endocannabinoids. 31, 43, 48 To our surprise, despite elevating AEA levels within the PAG, pharmacological and genetic FABP5 inhibition did not produce analgesic effects. Similar results were observed upon FABP inhibition within the RVM. This suggests that other brain regions may gate analgesia produced by FABP inhibitors such as the prefrontal cortex, wherein endocannabinoids/NAEs can exert analgesic effects. 51, [54] [55] [56] Our results demonstrating peripherally mediated analgesic effects of FABP inhibitors suggest a possible multifactorial involvement of FABP5 in inflammatory pain. In addition to its expression in nociceptors, FABP5 is also widely expressed in cells of the innate immune system. 57, 58 During inflammation, leukocytes release lipid metabolites such as prostaglandin E2 that sensitize nociceptors and induce pain, while FABP inhibition reduces the inflammatory output of leukocytes. [57] [58] [59] Therefore, it is likely that in addition to producing acute analgesic effects through modulation of endocannabinoid/NAE signaling in nociceptors, FABP inhibitors dampen the inflammatory output of leukocytes and reduce nociceptor sensitization, which is supported by the anti-inflammatory effects of FABP inhibitors.
15,32
Conclusions
FABPs regulate the intracellular transport and subsequently catabolism of endocannabinoids and NAEs. Our findings indicate that FABP inhibitors exert their analgesic effects through peripheral and supraspinal FABP inhibition mediated via activation of overlapping but distinct receptor systems. The peripherally mediated analgesic effects of FABP inhibitors coupled with their previously reported anti-inflammatory effects and low brain penetration 15, 32 suggests that the design of future peripherally restricted FABP inhibitors should be readily achievable.
